Join us at the
4th Annual International Raising C. diff. Awareness Conference
and Health EXPO
September 20th
DoubleTree by Hilton — Atlanta Airport
3400 Norman Berry Drive, Atlanta,Georgia 30344 USA
1-404-763-1600
It will not be like any other educational conference,
On September 20th the International “Raising C. diff. Awareness” Conference will be one paired with
world-renowned topic experts and presentations on state-of-the-art health care topics pertaining to a leading Healthcare-Associated Infection (HAI); — Clostridium difficile
*Prevention
*Treatments
*Research
*Clinical trials and studies
*Microbiome research
*Infection Prevention
*Environmental Safety
*Fecal Microbiota Restoration and Transplants
*A C. diff. Infection Survivor Panel
……………………and much more.
We welcome Dr. Clifford McDonald, MD, Key Guest Speaker and Chair of this international conference. Dr. McDonald is Senior Advisor for Science and Integrity, Division of Healthcare Quality Promotion at the Center of Disease Control and Prevention (CDC) with main interests in epidemiology and prevention of Healthcare-Associated Infections (HAI’s),
especially Clostridium difficile infections, and the prevention of antimicrobial resistance,
Dr. McDonald will be joining fellow world-renowned topic experts to discuss the burden of
C. difficile infections with the risk factors pertaining to current and emerging treatment options along with the importance of applying evidence-based clinical approaches to the prevention of a C. difficile infection (CDI), one of the leading community and Hospital-Acquired Infections.
……………………………………………………………………………………………..
Dr. Arjun Srinivasan, MD, is Associate Director for healthcare-associated infection prevention programs in the Division of Healthcare Quality Promotion at the Center for Disease Control and Prevention’s National Center for Emerging and Zoonotic Infectious Diseases. Dr. Srinivasan is also a captain in the US Public Health Service. An infectious disease doctor, Dr. Srinivasan oversees several CDC programs aimed at eliminating healthcare-associated infections and improving antibiotic use. For much of his CDC career, Dr. Srinivasan ran the healthcare outbreak investigation unit, helping hospitals and other healthcare facilities track down bacteria and stop them from infecting other patients. Today, Dr. Srinivasan leads CDC’s work to improve antibiotic prescribing and works with a team of CDC experts researching new strategies to eliminate healthcare-associated infections. Topic: TBA
Dr. Mark Wilcox MD, FRCPath, is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK. He was formerly the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. Dr. Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection Committee and is a member of the HPA’s Program Board on Healthcare Associated Infection & Antimicrobial Resistance. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents. Topic: TBA
Dr. Simon M. Cutting, PhD, Professor of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus. After spending 7 years in the renowned laboratory of Professor Richard Losick at Harvard University Biological Laboratories (USA) he spent 3 years as an Assistant Professor at the University of Pennsylvania Medical School in Philadelphia. He returned to the UK in 1996 and since then has worked on developing bacterial spores as novel oral vaccines at
Royal Holloway, University of London. The Cutting lab has developed a number of prototype oral vaccines and is now entering a ‘first in man’ phase 1/IIa clinical trial of a prototype oral vaccine to Clostridium difficile (see www.cdvax.org). His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors (see SporeGen.com).
Presentation Topic: TBA
Dr. David Cook, PhD; A scientist and entrepreneur who has held senior operating and management positions in the biotechnology industry over his 20-year career. Before joining Seres Therapeutics, he was the chief operating officer for the International AIDS Vaccine Initiative, a global R&D organization whose mission is to develop a safe, globally accessible vaccine for HIV. Prior to IAVI, David was the founding CEO at Anza Therapeutics, a biotechnology start-up developing a novel microbial vaccine platform to induce cellular immune responses to fight or prevent diseases such as cancer, hepatitis C, malaria and tuberculosis. He is also a co-inventor on over twenty-five patents. He received his undergraduate degree from Harvard College and his PhD in chemistry from the University of California, Berkeley. Dr Cook is presently Executive Vice President of R&D, Chief Scientific Officer with Seres Therapeutics, Inc..
Presentation Topic: “The role of the microbiome in resisting C. difficile infection and the mechanism of Ecobiotic drugs.”
Dr. Rosie Lyles, MD — Dr. Lyles has an extensive educational background includes the Texas Woman’s University, Denton, Texas BS, Biology, St. Matthew’s School of Medicine, Grand Cayman MD 05/04 Medicine – St. Joseph’s College, Standish, Maine MHA 05/06 Health Services Administration – University of Illinois at Chicago MSc 2014 Clinical and Translation Science. Dr. Lyles currently serves as the primary liaison for Client’s Healthcare division, in a major healthcare corporation, as a department head to relevant professional, research and academic institutions, public health agencies, and forums. Her role provides strategic guidance and assists with the development and implementation of a plan for clinical/scientific support of marketing initiatives. This includes overall responsibility for public health message development, publication planning, key opinion leader development and provides relevant input into the clinical and product intervention design and development. Topic: TBA
Dr. Charles Darkoh, PhD. Dr. Darkoh and his laboratory team’s approach to make the toxins inactive is built upon a previous discovery they made in which they identified new compounds that are associated with the prevention of toxin production. In this current study they will evaluate the compounds on different strains of C. diff and examine the efficacy of a cocktail of these compounds that could work as a combination therapy to prevent infection. Dr. Darkoh has a long history of making major contributions to the science of C. Diff treatment and prevention, starting with his doctoral work in the lab of his mentor Dr. Herbert DuPont, MD, MACP, Director of the Center for Infectious Diseases. Topic: TBA
Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Most recently Lee was Chief Administrative Officer of the Schulze Diabetes Institute at the University of Minnesota, Minneapolis, MN and is the former president and chief executive officer of Inlet Medical. Inlet Medical was sold to Cooper Surgical in 2006. Lee will introduce Rebiotix Inc., a biotechnology company founded in 2011 in Roseville, MN to revolutionize the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome The company is developing an entirely new kind of biological drug designed to reverse pathogenic processes responsible for disease through the transplantation of live human-derived microbes into a sick person’s intestinal tract.
Presentation Topic: Blazing a Trail with the Gut Microbiome
Dr. Rahma Wehelie, PhD, is a senior scientific officer at LifeClean International AB. From 2015 to June, 2015 Dr. Wehelie was a senior research scientist and consultant at MoreinX AB in Uppsala, Sweden. From 2012 to 2014, Dr. Wehelie was Managing Director at Ridales Healthcare Consulting, Enköping, Sweden and was responsible for cancer management project. Dr. Wehelie worked as a senior research scientist and studied the molecular mechanisms of interaction between pathogenic bacteria Helicobacter pylori
(H. pylori), human gastric epithelial cells, and CD46 transgenic
mice at Stockholm University. Dr. Wehelie did her postdoctoral training at
Uppsala University and studied host bacterial interactions in H. pylori infection
from 2007 to 2008. Dr. Wehelie was awarded PhD in Biochemistry from
Swedish University of Agricultural Sciences in 2006, received an undergraduate
degree in Bachelor of Science at the Department of Pharmaceutical Biosciences,
Uppsala University in 2000, and Advanced Diploma in Biological Technology Industrial Microbiology, School of Engineering Technology and Applied Science, Centennial College,
Toronto, Canada in 1996.
Presentation Topic: Dr Wehelie will be discussing LifeClean’s research, development and production eliminating Clostridium difficile, Norovirus, and other multidrug-resistant bacteria
Dr. Hudson Garrett, Jr., PhD, MSN, MPH, FNP, CSRN, VA-BC, CDONA,FACONA,DON-CLTC™ , C-NAC™ , PLNC: Dr. Hudson Garrett is currently employed as the VP, Clinical Affairs for PDI, Inc. and NIce-Pak, and is responsible for the global Clinical Affairs program and also the Medical Science Liaison program for all divisions within the company. He holds a Bachelor of Science degree in Biology/Chemistry and Nursing, a dual Masters in Nursing and Public Health, Post-Masters Certificate as a Family Nurse Practitioner, a Post-Masters Certificate in Infection Prevention and Infection Control and a PhD in Healthcare Administration and Policy. He has completed the Johns Hopkins Fellows Program in Hospital Epidemiology and Infection Control, and the CDC Fundamentals of Healthcare Epidemiology program, and is board certified in family practice, critical care, vascular assess, moderate sedation, legal nurse consulting, and a director of nursing in long term care. Dr. Garrett is also a Fellow in the Academy of National Associations of Directors of Nursing Administration in Long Term Care. Presentation Topic: TBA
…………………………………………………………………
C Diff Foundation reservation site!
Book by August 19th to reserve your room!
To create a reservation please click on the DoubleTree By Hilton Logo.
……………………………………………………………………………………………..
A suggested travel coordinator, for your convenience
Michael Beckman — Team Leader, Liberty Travel, 467 Washington Street, Boston, MA 02111
617-936-2435
Michael.Beckman@flightcenter.com
………………………………………………………………………………………………
We would like to sincerely thank the following Sponsors for their continued support and joining the Foundation in
Raising C. diff. Awareness worldwide.
- Enjoy visiting our Exclusive Corporate Sponsors websites by simply clicking on their logos below *
GOLD SPONSORS
SILVER SPONSORS
BRONZE SPONSORS
Follow us on Twitter @cdiffFoundation
#Cdiff2016
